Solara Active Pharma Sciences reported a strong Q1 FY27 with revenue up 20% YoY to ₹384 crore and PAT rising 55% to ₹16.3 crore. The company also significantly reduced its net debt by ₹135 crore.
Solara Active Pharma Sciences Q1 FY27 Results: Strong Growth and Deleveraging
Solara Active Pharma Sciences reported overall revenue of ₹384 crore and Profit After Tax (PAT) of ₹16.3 crore for the first quarter of FY27. Reader Takeaway: Base business thrives, but Ibuprofen segment challenges persist; debt reduction is a key positive. ## What just happened Solara Active Pharma Sciences announced its financial results for Q1 FY27. The company posted an overall revenue of ₹384 crore, marking a 20% year-on-year (YoY) increase. Profit After Tax (PAT) saw a significant jump of 55% YoY to ₹16.3 crore. EBITDA grew 10% YoY to ₹63.5 crore. The base business revenue was ₹307 crore, up 24% YoY. The company achieved its highest EBITDA and PAT in 18 quarters. ## Why this matters The strong performance in the base business and the substantial 55% YoY increase in PAT indicate a successful operational turnaround. The significant reduction in net debt by ₹135 crore to ₹479 crore as of June 30, 2026, improves the company's financial health and reduces leverage to 1.9x. ## The backstory Solara Active Pharma Sciences is a pharmaceutical company focused on active pharmaceutical ingredients (APIs). In recent periods, the company has been working on improving operational efficiency, expanding its core business, and managing its debt levels. The Ibuprofen segment has been a point of concern due to profitability challenges. ## What changes now This quarter's results suggest positive momentum driven by the core business. The company is prioritizing operational efficiency through debottlenecking and optimizing working capital. The strategic review of the Ibuprofen segment, expected to conclude in H1 FY27, could lead to further performance improvements if successful. ## Risks to watch The Ibuprofen segment continues to be a drag, reporting a -12% EBITDA margin, which requires ongoing monitoring. Additionally, geopolitical events like the West Asia crisis can impact input costs and raw material availability, potentially affecting production. ## Peer comparison While specific peer comparisons are not detailed in the filing, Solara's reported revenue growth of 20% and PAT growth of 55% in Q1 FY27 demonstrate a potentially stronger performance relative to some industry averages, especially in the API segment, provided peers faced similar macro challenges. ## Context metrics (time-bound) * **Net Debt Reduction:** ₹135 crore in Q1 FY27. * **Target Net Debt:** Sub-₹450 crore by March 2027. * **EBITDA Margin (Base Business):** Not explicitly stated, but Base Business EBITDA was ₹72 crore on ₹307 crore revenue. * **Ibuprofen EBITDA Margin:** -12%. ## What to track next Investors should closely watch the strategic review outcome for the Ibuprofen segment and the company's ability to maintain the growth momentum in its base business. Monitoring the impact of geopolitical issues on raw material costs and supply chains will also be crucial.
